ArticleBioengineering & translational medicine2020
Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization.
Article in Bioengineering & translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 59 citations in OpenAlex.
- Stability of bacteriophages in spray-dried polymeric formulations: Effect of excipient polyvinylpyrrolidone glass transition temperature and molecular weight.Bioengineering & translational medicine · 2026Article
- Bacteriophage Therapy: Overcoming Antimicrobial Resistance Through Advanced Delivery Methods.Molecules (Basel, Switzerland) · 2026Review
- Bacteriophages targetingFrontiers in microbiology · 2026Review
- Latest Advances in Inhalable Dry Powder Bacteriophage Therapy for Pulmonary Infections.Pharmaceutics · 2025Review
- Long-term Storage Stability of Inhalable Phage Powder Formulations: A Four-Year Study.The AAPS journal · 2025Article
- Powder aerosol formulation of Pseudomonas aeruginosa bacteriophage for pulmonary delivery.International journal of pharmaceutics · 2025Article
- Formulation of Bacteriophage for Inhalation to Treat Multidrug-Resistant Pulmonary Infections.Kona : powder science and technology in Japan · 2025Article
- Review
- An Edible Biopolymeric Microcapsular Wrapping Integrating Lytic Bacteriophage Particles forAntibiotics (Basel, Switzerland) · 2023Article
- EudragitPharmaceutics · 2023Article
- Advancements in Particle Engineering for Inhalation Delivery of Small Molecules and Biotherapeutics.Pharmaceutical research · 2022Review
- Enhancing the Stability of Bacteriophages Using Physical, Chemical, and Nano-Based Approaches: A Review.Pharmaceutics · 2022Review
- Inhaled Delivery of Anti-Pseudomonal Phages to Tackle Respiratory Infections Caused by Superbugs.Journal of aerosol medicine and pulmonary drug delivery · 2022Review
- Manufacturing Stable Bacteriophage Powders by Including Buffer System in Formulations and Using Thin Film Freeze-drying Technology.Pharmaceutical research · 2021Article
- Article
- Manufacturing Bacteriophages (Part 2 of 2): Formulation, Analytics and Quality Control Considerations.Pharmaceuticals (Basel, Switzerland) · 2021Review
- The Influence of Formulation Components and Environmental Humidity on Spray-Dried Phage Powders for Treatment of Respiratory Infections Caused byPharmaceutics · 2021Article
- Bacteriophage-Delivering Hydrogels: Current Progress in Combating Antibiotic Resistant Bacterial Infection.Antibiotics (Basel, Switzerland) · 2021Review
- Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections.Frontiers in cellular and infection microbiology · 2021Review
- BioTM buzz (volume 5, issue 2).Bioengineering & translational medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Recent heightened interest in inhaled bacteriophage (phage) therapy for combating antibacterial resistance in pulmonary infections has led to the development of phage powder formulations. Although phages have been successfully bioengineered into inhalable powders with preserved bioactivity, the stabilization mechanism is yet unknown. This paper reports the first study investigating the stabilization mechanism for phages in these powders. Proteins and other biologics are known to be preserved in dry state within a glassy sugar matrix at storage temperatures (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.